GlassScriptPhysician profile
Ramya Raghupathi
NPI 1720334113
$13,942.03
in general payments reported to CMS, 2019-2025
11 companies · $7,602 in 2025
The $7,602 reported for 2025 was more than what 90% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.08 · 2021: $810 · 2022: $4,469 · 2023: $510 · 2024: $530 · 2025: $7,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,800 · Food and Beverage: $2,303 · Travel and Lodging: $1,239 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,800.00 |
| Food and Beverage | $2,303.39 |
| Travel and Lodging | $1,238.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $8,631.43 | 2022-2025 | Fintepla |
| Jazz Pharmaceuticals INC. | $1,256.48 | 2024-2025 | |
| Neuropace, INC. | $976.09 | 2024-2025 | |
| Dixi Medical USA Corp | $823.57 | 2022 | |
| Aquestive Therapeutics, INC. | $660.00 | 2021 | |
| Sk Life Science, INC. | $558.60 | 2022-2025 | Xcopri |
| Neurelis, INC. | $507.64 | 2023-2025 | Valtoco |
| Livanova USA, INC. | $300.00 | 2023 | Vns Therapy |
| Greenwich Biosciences, INC. | $149.78 | 2021 | |
| Acadia Pharmaceuticals INC | $57.36 | 2025 | Daybue |
| Amgen INC. | $21.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramya Raghupathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.